Published · Liberia

China’s Antitrust Regulator Expands Compliance Outreach to Tech and Pharma Firms in Shanghai and the Yangtze River Delta

An SAMR compliance workshop in Shanghai signals closer antitrust scrutiny for AI, quantum technology, and pharmaceutical companies. Here is what foreign founders setting up or running a China entity should know about building antitrust compliance into their operations.

Practical Takeaways for Foreign Founders

The State Administration for Market Regulation (SAMR) held its fifth antitrust compliance workshop of 2026 in Shanghai on 29 October. The session was aimed at technology-driven businesses — including artificial intelligence and quantum technology companies — as well as firms in active pharmaceutical ingredients and innovative drugs. For foreign founders, the message is straightforward: antitrust compliance is no longer a concern only for large incumbents. It is becoming part of the operating baseline for companies registering and running a business in China, particularly in sectors the government regards as strategically important.

The workshop combined legal education with analysis of typical cases. Its stated purpose was to help businesses identify, assess, and prevent antitrust risk, compete lawfully, and operate in compliance. SAMR framed a fair competition environment as a way to support the building of an international science and innovation center in Shanghai and the wider Yangtze River Delta.

Why This Matters at the Registration Stage

Antitrust compliance is often treated as a post-launch issue. In practice, several decisions made during company formation shape a founder’s later exposure.

Choosing the right entity

A wholly foreign-owned enterprise, a Sino-foreign joint venture, and a representative office each carry different governance and reporting obligations. Joint ventures in particular can raise questions about control, information exchange, and coordinated conduct between shareholders. Founders should think about how decision-making rights and information flows are structured before signing the joint venture contract.

Defining the business scope

The registered business scope determines what activities the entity may lawfully conduct. For AI, quantum technology, and pharmaceutical companies, the scope should match the actual commercial plan. A mismatch can create both licensing problems and uncertainty about which regulatory regimes apply.

Mapping the competitive landscape

Before entering a market, founders should understand who their competitors, suppliers, and distribution partners will be. This helps identify situations — such as exclusivity arrangements or joint bidding — that may later require antitrust review.

Compliance Expectations SAMR Is Emphasizing

SAMR used the workshop to restate several expectations for market participants. These are framed as general compliance duties, not new registration requirements, but they are relevant to how a newly established China company should be governed.

• Take primary responsibility for antitrust compliance. Companies are expected to treat compliance as their own obligation rather than an external constraint.
• Build an internal compliance management system. This typically includes written policies, assigned responsibility, training, and internal review procedures.
• Embed compliance across the entire production and operating chain. Procurement, pricing, distribution, licensing, and partnerships all fall within scope.
• Proactively prevent antitrust risk. The emphasis is on identifying and managing risk before it becomes an enforcement matter.

For a foreign-invested company, these expectations argue for putting compliance structures in place early — ideally alongside entity registration — rather than retrofitting them after commercial operations begin.

The Regulatory Context: Fair Competition and Factor Flows

SAMR described antitrust enforcement as serving two goals: protecting fair competition and stimulating innovation. It also referred to removing bottlenecks in the flow of production factors and to creating a market environment that is fair, transparent, stable, and predictable.

For foreign founders, the practical reading is that China’s antitrust regulator is positioning compliance as part of the investment climate, not simply as a penalty regime. Companies that can demonstrate a functioning compliance system may find regulatory interactions smoother, particularly in sectors where licensing and market access decisions involve multiple agencies.

Sectors in Focus

The workshop specifically targeted two clusters.

Technology companies

Artificial intelligence and quantum technology firms operate in markets where standards, data access, and platform relationships can raise competition issues. Founders in these fields should pay attention to how they structure partnerships, licensing, and access to computing or data resources.

Pharmaceutical companies

Active pharmaceutical ingredient and innovative drug businesses face antitrust scrutiny in many jurisdictions, and China is no exception. Distribution arrangements, exclusivity terms, and pricing conduct are areas where compliance policies should be clear from the outset.

Who Participated

The event was organized with participation from SAMR’s First Antitrust Enforcement Division, the Shanghai, Jiangsu, Zhejiang, and Anhui market regulation bureaus, and SAMR’s competition policy center. More than 100 businesses and industry associations joined either in person or online. The regional spread reflects the Yangtze River Delta’s role as a hub for foreign investment and technology companies.

What Foreign Founders Should Do Next

Founders planning a China entity, or already operating one, can take several practical steps that align with the themes of the workshop.

• Review the business scope and licenses against the actual commercial plan, especially for regulated technology and pharmaceutical activities.
• Draft an antitrust compliance policy covering pricing, distribution, trade associations, competitor contacts, and joint ventures.
• Assign compliance responsibility to a named function or officer within the China entity.
• Train commercial teams on what information may and may not be exchanged with competitors or partners.
• Keep records of compliance decisions, training, and internal reviews.
• Monitor regulatory developments in the Yangtze River Delta, where enforcement and policy attention are concentrated.

None of these steps replaces tailored legal advice. China’s antitrust rules interact with sector regulation, foreign investment rules, and local market conditions, and the right approach depends on the specific business model.

Bottom Line

SAMR’s Shanghai workshop is a signal that antitrust compliance is being folded into the broader framework for doing business in China. For foreign founders, the registration phase is the right time to think about entity structure, business scope, and internal controls — not after the first commercial dispute or regulatory inquiry. Building compliance into the company from the beginning is both a risk-management measure and a practical way to operate with greater predictability in a large and complex market.

Need help registering or operating a company in China? Foreign founders can contact ChinaMNC on WhatsApp or WeChat at +86 153 1898 8535 for assistance with entity setup, documentation, and ongoing compliance.

This summary is based on information published by the relevant Chinese government website and is general information, not legal or tax advice.